Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
about
Role of RANKL inhibition in osteoporosisMaintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's DiseaseOestrogen therapy for urinary incontinence in post-menopausal womenSelective estrogen receptor modulators (SERMs) for uterine leiomyomasDenosumab for the treatment and prevention of postmenopausal osteoporosisOestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal womenSelective estrogen receptor modulators (SERMs) for uterine leiomyomasThe aging spine: new technologies and therapeutics for the osteoporotic spineEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenTiming and duration of menopausal hormone treatment may affect cardiovascular outcomesEstradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and betaSelective androgen receptor modulators in preclinical and clinical developmentDrugs for pre-osteoporosis: prevention or disease mongering?Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifeneOsteoporosis and its managementTamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisAn Increased Risk of Osteoporosis during Acquired Immunodeficiency SyndromeIsoflavones and women's healthHormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trialsA review of anabolic therapies for osteoporosisFuture possibilities in the prevention of breast cancer: breast cancer prevention trials.Evaluation of easily measured risk factors in the prediction of osteoporotic fractures.Treating osteoporosisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchPostmenopausal syndromeMedical treatment of uterine leiomyomaThe evolution of selective estrogen receptor modulators in osteoporosis therapyThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practicePostmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspectiveEpidemiology and management of osteoporosis in the People's Republic of China: current perspectivesDenosumab for the treatment of osteoporosisAn overview on the treatment of postmenopausal osteoporosisDenosumab: mechanism of action and clinical outcomesParathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosisCyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivoBone anabolics in osteoporosis: Actuality and perspectivesBreast cancer chemoprevention: old and new approachesNonsurgical Treatment Strategies after Osteoporotic Hip Fractures.The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
P2860
Q21195417-B3CBE078-FF1D-47C5-9999-C096639E49F5Q22242347-8AACDA67-AD0F-468E-B032-F26ADD9CD8E4Q24198065-571251A9-ACC8-451E-98C8-EDC33D0CACE0Q24198863-B575A0A9-FA43-43DB-AFC2-1466116F598AQ24201859-9FBF9A6B-DC0D-4716-8665-C4EA3016CB89Q24235377-A6B9AAD0-6962-4E88-BB81-2EDDEE1E6239Q24242980-3B02EFAF-ECCE-486D-B6F5-F78E24C64748Q24609687-BEAA797B-C8C4-4EE0-8A4F-869C2A268A85Q24612411-BA00C109-3B59-4974-9987-DA1D3EFBEE11Q24626206-0189B0F5-73F5-4B42-BDA6-36166B1260BDQ24632806-4364BCF7-107A-4C74-8593-D7E8FCA1903AQ24645579-C63F7AFB-421E-4923-9E08-C933F8C079CAQ24649128-37ABB05C-0E6D-4062-B1DC-BB013E0A092EQ24652524-44DF3864-292F-40D1-9189-A548EFCD964BQ24670075-1A59D3C3-7A89-4B01-9A67-B4585AFB0C67Q24670339-7243F558-B851-47C9-B21E-0B4841337B51Q24680238-C4763254-FA77-4ACB-BB43-51D8E063362AQ24791238-2FCB9B2D-F968-4DFB-BB7D-F0A049ABC32FQ24795093-0D04A0B3-0C57-4275-BF5F-159A01BF9A6EQ24795111-763B77B1-F33C-40F8-B69E-6E3839470CDEQ24797842-6941DF96-9F52-4E38-8649-FD9078BD50E0Q24803259-6BE21B82-071C-4AA9-8685-E118389CFC3BQ24813492-FF95853F-29DB-4749-9DCC-E67234134807Q26747363-3DB81C68-7A64-43E8-868D-EC612B2CD3F7Q26782621-46F5A54E-AB87-4333-9893-FEB5B3A43A7BQ26795412-F0F888E9-A974-4462-A9C9-1E8BF6EBBE5FQ26824379-907BE3E8-04A1-44E5-9C1B-60010B318901Q26827973-A1EE2E93-3AFD-4BE7-9B45-DE1F5DF8FD73Q26830744-BEC6D918-BEF2-4F6A-86C3-515E6A76C70BQ26864207-C255C001-63C6-4C9E-8C0A-B266FCC3A524Q27005978-04946757-1F77-44B8-93EB-79F5EE8F11B8Q27009275-DA220C89-51F4-44DC-8C0F-1B202F35DBF6Q27013070-36170D88-9439-474C-98D6-3FA06577745EQ27015899-4FDB6C76-09D7-4016-98A0-D4557268D034Q27024513-3E2A2D56-F852-43F4-86B4-7CF95D1E0C76Q27302901-5A4B2F79-D731-4146-9F8D-C117C395DEE7Q27691122-D9118E05-0952-4537-82F0-48A9B9BC9D97Q27693259-3613396A-9ABA-4892-A982-6C636C560041Q27693845-36BED81B-7C2B-4E8A-9BF1-440B2C3C6A40Q28080673-75B04E5B-0A9D-4BB9-8DB8-14EC886037D7
P2860
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Reduction of vertebral fractur ...... aluation (MORE) Investigators.
@en
Reduction of vertebral fractur ...... comes of Raloxifene Evaluation
@nl
type
label
Reduction of vertebral fractur ...... aluation (MORE) Investigators.
@en
Reduction of vertebral fractur ...... comes of Raloxifene Evaluation
@nl
prefLabel
Reduction of vertebral fractur ...... aluation (MORE) Investigators.
@en
Reduction of vertebral fractur ...... comes of Raloxifene Evaluation
@nl
P2093
P356
P1476
Reduction of vertebral fractur ...... aluation (MORE) Investigators.
@en
P2093
B Ettinger
B H Mitlak
C Christiansen
H K Genant
J R Zanchetta
J Stakkestad
K E Ensrud
P304
P356
10.1001/JAMA.282.7.637
P407
P577
1999-08-01T00:00:00Z